Monte Rosa Therapeutics (GLUE) Total Current Liabilities (2020 - 2026)

Monte Rosa Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $71.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 19.96% year-over-year to $71.0 million; the TTM figure through Mar 2026 stood at $71.0 million (up 19.96% YoY), while the FY2025 annual figure was $64.2 million, down 59.09% from the prior year.
• Total Current Liabilities was $71.0 million for Q1 2026 at Monte Rosa Therapeutics, up from $64.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $156.9 million in Q4 2024 to a low of $12.5 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $44.9 million across 5 years, with a median of $41.6 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities soared 236.85% in 2024, then sank 59.09% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $25.6 million in 2022, then soared by 82.22% to $46.6 million in 2023, then jumped by 236.85% to $156.9 million in 2024, then tumbled by 59.09% to $64.2 million in 2025, then advanced by 10.63% to $71.0 million in 2026.
• The last three Total Current Liabilities figures came in at $71.0 million (Q1 2026), $64.2 million (Q4 2025), and $61.4 million (Q3 2025), per Business Quant data.